BioSig’s PURE EP System to Support Live Patient Cases during EPLive 2020
November 30 2020 - 11:00AM
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that its flagship technology would be
featured in several live cases broadcast during EPLive 2020, the
fifth international symposium on complex arrhythmias.
EPLive is an intensive, two-day educational meeting for
practicing clinical cardiac electrophysiologists, electrophysiology
fellows, and general cardiologists interested in treating complex
cardiac arrhythmias. A total of 21 live and 13 recorded cases will
broadcast from the new, state-of-the-art Electrophysiology Center
at St. David’s Medical Center in Austin, TX, with expert commentary
and will serve as the primary teaching tool.
The PURE EP™ System will be highlighted in several patient cases
conducted live by Andrea Natale, M.D., F.H.R.S., F.A.C.C.,
F.E.S.C., Executive Medical Director of TCAI and EPLive course
director, and Joseph Gallinghouse, M.D.
“We are thrilled to be included in EPLive, a very unique
physician education event, and we appreciate all the effort that
went into making this important conference a reality amidst the
global pandemic. We are grateful to Dr. Natale and his colleagues
at TCAI for the outstanding support they continue to provide to our
team and to the entire faculty of EPLive for their dedication to
improving patient outcomes through the introduction of
sophisticated educational tools and techniques for the benefit of
the global physician audience,” commented Kenneth L. Londoner,
Chairman and CEO of BioSig Technologies, Inc.
“More than 350 cases have been performed with the PURE EP™
System so far, and we are thrilled to see the value that additional
physiologic information can provide across all types of
cardiac arrhythmias. We are honored to be part of EPLive, and
we look forward to continuing this exciting journey with the entire
EP community,” commented Olivier Chaudoir, Sr. Director of
Marketing at BioSig Technologies, Inc.
Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical
Center was the first clinical installation site for the evaluation
of BioSig’s PURE EP™ System. To date, more than 350 patient cases
have been completed with the PURE EP™ System by 25
electrophysiologists across several clinical sites.
For more information about the event, please visit
www.ep-live.com.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company's first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024